RxDoctor Payments Data

Chau Vu, MD

Nephrology · Webster, TXNPI 1689671497

Payments from drug & device makers

$4,313in general payments, 2019–2025

Across 130 payments — averaging $33.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Painteq LLC$2K
  • Mallinckrodt Hospital Products Inc.$477
  • AstraZeneca$370
  • Abbott$302
  • Amgen$276
  • Dermavant Sciences, Inc.$242
  • plus $912 from 18 others

What the payments were for

  • Food & beverage$4,28999%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,313 in reported general payments places this provider in the 65th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$263,028
Medicare patients
429
Services billed
2,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol66$62,370
JardianceEmpagliflozin23$25,784
VelphoroSucroferric Oxyhydroxide14$22,544
ProsolParenteral Amino Acid 20% No.180$21,351
Sevelamer Carbonate50$13,264
ClinisolParenteral Amino Acid 15% No.512$4,317
Allopurinol272$3,101
Sodium Polystyrene Sulfonate40$2,553
Tamsulosin Hcl156$2,180
Potassium Chloride62$1,905
Bumetanide44$1,786
Calcitriol62$1,604
Eplerenone14$1,378
Metolazone42$1,373
Torsemide46$1,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$370$62,37066 claims
Boehringer IngelheimJardiance$28$25,78423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →